Ocean Biomedical, Inc. Common Stock
OCEA
OCEA was delisted on the 23rd of April, 2025.
26 hedge funds and large institutions have $81.8M invested in Ocean Biomedical, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
+$7.49M |
| 2 |
SCM
Saba Capital Management
New York
|
+$7.25M |
| 3 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$6.73M |
| 4 |
ASM
ATW SPAC Management
New York
|
+$5.99M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$5.99M |
Top Sellers
OCEA Hedge Fund Activity: Q4 2021 in Review
26 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ocean Biomedical, Inc. Common Stock (OCEA) for Q4 2021, worth a combined $81.8M.
Buyers outnumbered sellers: 26 funds opened new OCEA positions and 0 closed out — a net gain of 26 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Mizuho Securities USA, opening a new position worth an estimated $7.49M.
- 26 institutional investors held Ocean Biomedical, Inc. Common Stock (OCEA) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $81.8M of Ocean Biomedical, Inc. Common Stock stock for Q4 2021.
- 26 funds opened new Ocean Biomedical, Inc. Common Stock positions in Q4 2021 and 0 closed out, a net change of +26 holders.
- The largest Ocean Biomedical, Inc. Common Stock buyer in Q4 2021 was Mizuho Securities USA, an estimated $7.49M added.
Based on aggregated 13F filings for Q4 2021.